Novo Nordisk Seeks To Block Sale Of Exubera, Claims Patent Infringement
This article was originally published in The Pink Sheet Daily
Executive Summary
The insulin maker says Pfizer's Exubera infringes Novo's patents covering inhaled insulin.
You may also be interested in...
Lilly/Alkermes Broaden Inhaled Insulin Manufacturing Agreement
The update ensures adequate supplies of insulin powder “if and when” the AIR inhaled insulin system is launched, Lilly told “The Pink Sheet” DAILY.
Lilly/Alkermes Broaden Inhaled Insulin Manufacturing Agreement
The update ensures adequate supplies of insulin powder “if and when” the AIR inhaled insulin system is launched, Lilly told “The Pink Sheet” DAILY.
Novo Nordisk To Ramp Up Diabetes Sales Force In 2007
Novo Nordisk tells “The Pink Sheet” DAILY it has started recruiting reps; it intends to add 700 next year.